.Merck defeats incomes expectations, increases sales outlook on solid need for leading medications like Keytruda CNBCMerck & Co. (MRK United States) Trumps Earnings Projections as Keytruda Purchases Rise BloombergMerck Stock: Pharma Titan Posts Strong Outcomes, However Expectation Tumbles Short Client's Business DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck beats income and also purchases expectations amidst Keytruda strength, however delivers combined full-year outlook MarketWatch.